Refresher Course on Head & Neck Cancers
Refresher Course on Head & Neck Cancers

COURSE LEADERSHIP
Course Overview
Learning Objectives
- Understand the current status and future challenges of head and neck cancer.
- Accurately diagnose and stage the disease using imaging and molecular biomarkers.
- Know surgical and radiotherapy strategies for localized disease.
- Manage systemic therapies and organ preservation in locally advanced cases.
- Recognize and manage radiotherapy toxicities and support rehabilitation.
- Effectively participate in multidisciplinary case management.
- Understand immunotherapy principles and systemic treatments for advanced or recurrent disease.
- Address special situations including re-irradiation, salvage surgery, and de-escalation strategies.
- Support prehabilitation and rehabilitation and supportive care.
LANGUAGE
RESERVATION FEE
CME ACCREDITATION
The Refresher Course on Head & Neck Cancers, Brussels, Belgium 07/05/2026 - 09/05/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association,physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications .
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
ESO COLLEGE MEMBERSHIP
INSURANCE
CONTACTS - ORGANISING SECRETARIAT
Registration, arrivals & informal networking
Welcome and introduction of course aims & participants
Plenary introduction
Head & Neck Cancer in 2026 – Where We Stand and What We Are Missing
Lisa Licitra (IT)Diagnosis, staging and pathology
Clinical presentation, anatomy and patterns of spread in head & neck cancer
Sandra Schmitz (BE)Modern imaging & staging – CT, MRI
Thierry Duprez (BE)Pathology and molecular profiling – p16/HPV, EBV, and emerging biomarkers
Cécile Badoual (FR)Coffee break
Localised disease: surgery and radiotherapy
Surgical management of squamous cell carcinoma
Sandra Schmitz (BE)Principles of radiotherapy in head & neck cancer – target volumes, dose/fractionation and modern techniques (IMRT/VMAT, etc.)
Nicola Alessandro Iacovelli (IT)Neck management – elective vs therapeutic neck treatment, sentinel node and neck dissection strategies
Sandra Schmitz (BE)Lunch
Locally advanced disease & organ preservation
Concurrent chemoradiation – systemic therapy choices, timing and optimisation
Lisa Licitra (IT)Organ preservation in laryngeal and hypopharyngeal cancer
Felipe A. Calvo Manuel (ES)Neoadjuvant immunotherapy
Lisa Licitra (IT)Squamous cell carcinoma of unknown primary (HNCUP): diagnostic work-up and treatment strategies
Felipe A. Calvo Manuel (ES) Sandra Schmitz (BE)Coffee break
Toxicity management, supportive care & rehabilitation
Acute and late radiotherapy toxicities in head & neck cancer – prevention, early detection and multidisciplinary management
Nicola Alessandro Iacovelli (IT)Speech and swallowing rehabilitation
Sofiana Mootassim-Billah (BE)Multidisciplinary tumour board (MTD)
Tumour board: Selected clinical cases, presented by participants and discussed by the panel
Amil Družic (BA)End of the first day
Tumour board: Selected clinical cases, presented by participants and discussed by the panel
Basics in immunotherapy, biology and secondary effects
Advanced / recurrent disease & systemic therapies
Recurrent and metastatic head & neck cancer – systemic therapy sequencing and practical decision-making
Lisa Licitra (IT)Immunotherapy and biomarkers – PD-L1, combinations and real-world challenges
Lisa Licitra (IT)Coffee break
Special situations & interactive cases
Re-irradiation, oligometastatic disease and stereotactic approaches in head & neck cancer
Felipe A. Calvo Manuel (ES)Interactive case discussions: complex late toxicities, survivorship and quality of life (multidisciplinary perspectives)
Cécile Badoual (FR) Felipe A. Calvo Manuel (ES) Lisa Licitra (IT) Marta Porebiak (PL) Sandra Schmitz (BE)Salvage irradiation
Felipe A. Calvo Manuel (ES)Salvage surgery
Sandra Schmitz (BE)HPV/p16-positive oropharyngeal cancer: de-escalation approaches in 2026 (radiotherapy and systemic treatment)
Nancy Lee (US)Closing remarks & take-home messages
Amil Družic
Clinical Center University of Sarajevo, Radiotherapy Dept., Sarajevo 71000, BA
Cécile Badoual
Gustave Roussy, Dep. de Biologie et Pathologie Médicales, Paris, FR
Felipe A. Calvo Manuel
Clinica Universidad de Navarra, Dept. of Radiation Oncology, Madrid, ES
Jean-pascal Machiels
Institut Roi Albert II Cancer Center, Medical Oncology Department, Brussels, BE
Lisa Licitra
Fondazione IRCCS Istituto Nazionale dei Tumori, SC Oncologia Medica 3 Tumori Testa e Collo, Milano, IT
Marta Porebiak
SWPS University, Faculty of Psychology, Warsaw, PL
Nancy Lee
Memorial Sloan Kettering Cancer Center, ., New York, US
Nicola Alessandro Iacovelli
Fondazioe IRCCS Istituto Nazionale Tumori, SC Radioterapia 2, Milano, IT
Sandra Schmitz
Cliniques universitaires Saint-Luc, Brussels, BE
Sofiana Mootassim-Billah
Institut Jules Bordet, ., Brussels, BE
Thierry Duprez
Cliniques universitaires Saint-Luc, ., Brussels, BE
PARTICIPATION
- Candidates aged 30–45 years
- With 2–3 years of oncology experience
- Who have previously attended an ESO Masterclass
- Who are fluent in English
HOW TO APPLY
- Recommendation letter: A letter from your head of department or mentor, written on official hospital letterhead and signed.
- Curriculum Vitae (CV).
- Clinical case: Please use this template.
SELECTION PROCESS